Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18357964 | 1.00 | GAA (0.31) | GAACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL23512951 | 0.73 | — | — | |
| SCHEMBL11254456 | 0.72 | MMP2 (0.31) | — | |
| SCHEMBL38665655 | 0.72 | — | — | |
| SCHEMBL16673765 | 0.65 | — | — | |
| SCHEMBL7811435 | 0.62 | FAP (0.30) | — | |
| SCHEMBL7811433 | 0.62 | FAP (0.30) | — | |
| SCHEMBL9486743 | 0.62 | FAP (0.30) | — | |
| SCHEMBL4523110 | 0.62 | FAP (0.30) | — | |
| SCHEMBL1686983 | 0.62 | FAP (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107208-A1 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-114728953-B | Beta-lactams, process for their preparation and their use as antibiotics | 宁夏农林科学院 | 2024-04-09 | — | — | CN | disclosed |
| CN-114728953-A | Beta-lactam compounds, process for their preparation and their use as antibiotics | 宁夏农林科学院 | 2022-07-08 | — | — | CN | disclosed |
| CN-108778273-B | Bicyclic aryl monocyclic beta-lactam compounds and methods of use thereof for treating bacterial infections | 默沙东公司 | 2022-06-17 | — | — | CN | disclosed |
| US-11022602-B2 | Antibiotic-based conjugates and methods of use thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-06-01 | — | — | US | disclosed |
| EP-0342423-A2 | Heteroaroylhydrazide derivatives of monocyclic beta-lactam antibiotics | E.R. SQUIBB & SONS, INC. (US) | 1989-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11022602-B2 | Antibiotic-based conjugates and methods of use thereof | MRPL21, RDX, ABCB11 | GAA 258/4885CHRM2 4517/4885CHRM4 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.